

# DOLOBID™

(Diflunisal Tablets, USP)

250mg

## DOLOBID™ is Indicated

DOLOBID is indicated for:

- Mild to moderate pain
- Osteoarthritis
- Rheumatoid arthritis

## Eligible Patients with Commercial

**PAY \$0**  
\*See program rules & requirements.

**ina**  
PHARMACEUTICS

**BIN:** 610020  
**RxGROUP:** 99994206  
**MEMBER ID:** 55599416510

For issues submitting claims under this offer, please contact TrialCard help desk at 866-562-6818.  
Visit [InaPharmaRX.com](http://InaPharmaRX.com) for more details and fullprescribing information

*Insurance can pay as little as \$0.  
Restrictions apply.*

## IMPORTANT SAFETY INFORMATION ABOUT DOLOBID™

### WARNING: RISK SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS

#### Cardiovascular Thrombotic Events

- Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use (see **WARNINGS** and **PRECAUTIONS**).
- Dolobid is contraindicated in the setting of coronary artery bypass graft (CABG) surgery (see **CONTRAINDICATION** and **WARNINGS**).

#### Gastrointestinal Risk

- NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events (see **WARNINGS**).

Carefully consider the potential benefits and risks of **DOLOBID™** (Diflunisal Tablets, USP) and other treatment options before deciding to use **DOLOBID™**. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see **WARNINGS: Gastrointestinal Bleeding, Ulceration, and Perforation**)

#### Manufacture direct pricing

NDC	AWP	Package Size
74157-009-60	\$3,006.00	60 ct